AstraZeneca's Datroway recommended for EU approval as first-line treatment in metastatic triple-negative breast cancer

Nippon Shinyaku and Elixirgen Therapeutics enter option agreement for development and commercialisation of EXG-7001 for Duchenne Muscular Dystrophy

Vifor Fresenius and CSL announce European regulator recommends revoking TAVNEOS (avacopan) marketing authorisation

Flerie portfolio company Bonsai Biotherapeutics secures clinical trial approval for TOL2 in myasthenia gravis

MaaT Pharma to seek review after CHMP negative opinion on MaaT013 application

Racura Oncology doses first patient in Phase 1 lung cancer trial

NeuroSense reports Phase 2 proof-of-concept study results for PrimeC in Alzheimer's Disease

LyGenesis granted funding for research project to induce immune tolerance to pancreatic islet transplantation

Servier enrols first US patient in Phase Ib/II paediatric epilepsy study

FDA approves Merck's Keytruda combinations for first-line treatment of PD-L1-positive advanced triple-negative breast cancer

Dicot Pharma receives FDA clearance to start Phase 2b study of LIB-01 in US

CeleCor Therapeutics submits final section of zalunfiban (Disaggpro) New Drug Application to US FDA

Vascarta announces VAS-101 Phase I results in sickle cell disease patients

Cirius Therapeutics commences enrolment and dosing for Phase 2 study of CIR-0602K in type 1 diabetes

Lundbeck to present new Vyepti and bocunebart migraine data at EAN 2026